海外の治験の状況「前立腺癌」での検索結果
242件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A phase II study assessing whether biological markers can be used to determine response to treatment with radium-223 in patients with metastatic castration resistant prostate cancer (CRPC).
- Castrate resistant prostate cancer with bone metastases. MedDRA version: 17.0 Level: LLT Classification code 10005993 Term: Bone metastases System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- United Kingdom
- 2014-09-08
Authorised
- Study to evaluate the effect of food on the availability of the drug abiraterone administered at low doses with food (standard and fat food) before fasting normal dose in patients with advanced prostatic cancer resistant to castration that have progressed to docetaxel.
- metastatic prostatic cancer after castration-resistant progression to docetaxel MedDRA version: 16.0 Level: LLT Classification code 10036947 Term: Prostatic cancer metastatic System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2012-12-21
Authorised
- A Single Arm Phase II Study to assess the efficacy of intensified intravenous Melphalan in combination with a transplant of the patient's own blood stem cells for a maximum of three cycles in patients with castration-resistant prostate cancer (CRPC)
- castration resistant prostate cancer patients;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- United Kingdom
- 2012-09-14
Authorised
- ANTI-3-18F-FACBC IN COMPARISON TO 11C-CHOLINE PET/CT IN THE EVALUATION OF PATIENTS WITH SUSPECT PROSTATE CANCER RELAPSE
- ? Patients with prostate cancer treated with radical prostatectomy or radiotherapy presenting with suspect progression(rising PSA) of local or distant (lymphnodes or bones) already scheduled for a 11C-Choline PET/CT (performed at enrolment and during the follow-up) MedDRA version: 14.1 Level: HLT Classification code 10036908 Term: Prostatic neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2012-08-07
Authorised
- Phase II study of biweekly cabazitaxel in patients affected by castration resistant prostate cancer previously treated with docetaxel: evaluation of safety and quality of life.
- Subjects affected by metastatic castration refractory prostate cancer progressed or intolerant to a previous docetaxel-based chemotherapy.;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2012-08-06
Authorised
- Efficacy of the Acino goserelin 3.6 mg implant that is administered twice in two months in patients with prostate cancer and examination of goserelin and hormone levels in the blood after administration of the Acino goserelin 3.6 mg implant and the Zoladex® 3.6 mg implant in a smaller subgroup of patients.
- Locally advanced, recurrent, or metastatic carcinoma of the prostate indicated for endocrine therapy MedDRA version: 17.0 Level: LLT Classification code 10007462 Term: Carcinoma prostate System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Czech Republic, Germany, Poland
- 2011-08-08
Authorised
- An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001
- Hormone refractory prostate cancer MedDRA version: 14.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- United Kingdom
- 2007-01-04
Authorised
- Phase II study of Irofulven in AR-targeted and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients, who have a Drug Response Predictor (DRP™) indicating a high likelihood of response to Irofulven
- AR-targeted and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Denmark, Sweden
- 2017-10-27
Authorised
- Phase 1/2 trial of repeated dosing of therapeutic investigational product 177Lu-PSMA-R2 and imaging agent 68Ga-PSMA-R2 in patients with prostate cancer that has spread. The study will assess the safety of the therapeutic drug and how it is tolerated by the body, the movement of the therapeutic study drug and imaging agent in the body and the quantity of radioactivity taken by the organs and tumors.
- Patients with PSMA positive Metastatic Castration-resistant Prostate Cancer (mCRPC), and disease progression following previous systemic treatment for mCRPC. MedDRA version: 20.0 Level: HLT Classification code 10036908 Term: Prostatic neoplasms malignant System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain, United States
- 2018-06-20
Authorised
- A comparison of the radiopharmaceuticals rhenium-188-HEDP versus radium-223-chloride in patients with advanced prostate cancer refractory to hormonal therapy; the RaRe trial.
- Metastatic castration resistant prostate cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- Netherlands
- 2018-02-22
